Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (654)	2/26/2007 9:40:25 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Elizabeth, That's what I thought,that they had started a PIII of INGN241 for patients of head & neck tumors in combination with radiation therapy. Re: The video. I had not seen that, although was aware of many people going to China to receive Gendicine injections. It is now 4 Yrs,that the chinese have been using the P53 treatments. bio-tek.blogspot.com I don't know if the FDA will take in consideration some of the results that the chinese have been obtaining,but I suppose they won't.<g> It will take some action by patients & their relatives & the general public to put pressure on the politicians & the FDA. In some cancer patients where there is no available treatment, I see no reason why they shouldn't allow to try anything that theoretically could be of help, since there isn't much to loose. And it is better to allow trials on a clinically sound environment.The way things stand now it takes too many years & too much money to be able to try a potentially beneficial drug in such otherwise hopeless patients. But if many people see what is going on in China,things may start to change. Of course, that will cut down on the chances that we may get a good entry price for INGN's stock.<g> RAGL Bernard